



# “PAST, PRESENT AND FUTURE OF CORONARY SURGERY”

**Prof. Roberto R. Favaloro, MD**

*Favaloro Foundation University Hospital | Favaloro University, Buenos Aires, Argentina*

*President, International Scientific Board*

*MC Medicor | Izola, Slovenia*



**International Symposium – Cardiovascular Diseases - MC Medicor Slovenia**

**December, 2022**



# ***Disclosure***

***Prof. Roberto R. Favaloro, MD***

***Favaloro Foundation University Hospital | Favaloro University, Buenos Aires, Argentina***

***President, International Scientific Board***

***MC Medicor | Izola, Slovenia***

***I have no conflicts of interest and nothing to disclose.***



Special Article

## The present era of myocardial revascularization -- some historical landmarks

René G. Favaloro \*

*Guemes Hospital and the El Salvador University School of Medicine, Buenos Aires, Argentina*

TABLE 2

History of coronary bypass surgery.

### A. EXPERIMENTAL

- 1910 Alexis Carrel. Homologous carotid artery between the descending thoracic aorta and left coronary artery [41,42]  
1954 Murray and associates. Axillary or free carotid artery between the ascending aorta and coronary arteries with the use of heparin [43–45]  
1961 Mamiya and associates. Left subclavian artery and left coronary artery [46]  
1963 Sauvage and associates. External jugular vein between the descending aorta and left coronary artery [47]  
1966 Wakabayashi and associates. Saphenous vein graft, as we know it today [48–50] (reported in 1968)

### B. CLINICAL APPLICATION OF SAPHENOUS VEIN GRAFT

- 1962 Sabiston (reported in 1974) [51]. Saphenous vein graft to the right coronary artery (the patient died)  
1964 Garrett and associates (reported in 1973). First clinical success: saphenous vein graft to the anterior descending coronary artery [52]  
1966 Kahn (reported in 1971). Saphenous vein graft to the right coronary artery [53]  
1967 Cleveland Clinic team [15,25]  
1968 Johnson and associates from Milwaukee [21,22]

### C. EXPERIMENTAL MAMMARY-CORONARY BYPASS

- 1956 Thal and associates. To the circumflex coronary artery [54]  
1960 Goetz and associates. Nonsuture technique with tantalum rings to the anterior descending or circumflex coronary artery [55]  
1961 Mamiya and associates. To the right coronary artery [46]  
1964 Spencer and associates. To the circumflex coronary artery [56]

### D. CLINICAL APPLICATION

- 1960 Goetz and associates. To the right coronary artery [55]  
1966 Kolessov. To the anterior descending coronary artery [57]  
1968 Bailey and Hirose. To the right coronary artery [58]  
1968 Green and associates. To the anterior descending coronary artery with a microscope [29]  
1970 Cleveland Clinic team



# Mammary artery-coronary artery anastomosis as method of treatment for angina pectoris

*V. I. Kolessov, M.D.,\* Leningrad, U.S.S.R.*

## FOREWORD

The opinions concerning the management and surgical treatment of angina pectoris as expressed in this paper by Professor V. I. Kolessov are at variance with the concepts of many surgeons in the United States. Consequently, with the approval of Professor Kolessov, we asked Dr. Donald B. Effler to prepare a comment on this paper. Also included at the end of this paper, is Professor Kolessov's response to Dr. Effler's comment.

—Brian Blades, Editor

**Kolessov VI. *J Thorac Cardiovasc Surg.* 1967 Oct; 54(4):535-44**






Fig. 3. The special scissors for incising the smaller vessels.




Fig. 4. An end-to-side anastomosis (schema). The arrangement of the sutures.




Fig. 5. An end-to-side anastomosis (schema). The arrangement of the sutures.




Fig. 6. Drawing of an implantation of the inner mammary artery into the myocardium and mammary artery-coronary artery anastomosis.

# Development of Surgical Treatments for Coronary Artery Disease

Robert H. Jones, MD

Alexis Carrel described the first experimental coronary artery bypass surgery in an article presented to the American Surgical Association on May 5, 1910, titled "On the Experimental Surgery of the Thoracic Aorta and Heart."<sup>1</sup> Dr. W. W. Keen of Philadelphia discussed the paper and recalled observing Dr. Carrel perform a bilateral thoracotomy with transection and resuturing of the thoracic aorta of a dog in his laboratory at the Rockefeller Institute for Medical Research. Dr. Keen closed the discussion with these words: "The promise of human surgery that lies in these early experiments to determine the technique is something that is marvelous, and the next 10 or 15 years are going to see us operating successfully on the esophagus and the thoracic and abdominal aorta and possibly on the human heart itself." Dr. Keen's words were appropriate both in his enthusiastic recognition of the promise of Carrel's work and in his qualification on the timing of the extension of these surgical techniques to the human heart. It was 42 years before Carrel's experiments were repeated in animals and 52 years before similar operations were performed on humans. The events of those intervening years followed a circuitous route typical of medical progress (Tables 1 and 2). This story of the evolution of coronary artery bypass surgery is important general knowledge for surgeons because of the common use of this procedure today. This history also reminds us how obvious solutions to common clinical problems are easily overlooked. We must be careful to avoid this trap in our work.

This article was originally published as Surgical Residents' Newsletter Vol 3, No. 9, September 1992 in *Annals of Surgery*, Vol. 216, No. 3, 1992. From the Mary and Deryl Hart Professor of Surgery, Duke University Medical Center, Durham, NC.

Reprints: Robert H. Jones, MD, Department of Surgery, Box 2996, Duke University Medical Center, Durham, NC 27710. E-mail: jones060@mc.duke.edu.

Copyright © 2003 by Lippincott Williams & Wilkins  
0003-4932/03/23800-0121

DOI: 10.1097/01.sla.0000097779.45670.36

*Annals of Surgery* • Volume 238, Number 6S, December 2003

## THE ROAD TO CORONARY BYPASS GRAFTING

### Indirect Operations on the Coronary Vasculature

Alexis Carrel received the Nobel Prize in medicine in 1912 for his work on vascular suture and the transplantation of blood vessels and organs (Fig. 1). His 1910 presentation to the American Surgical Association detailed much of the work for which the Nobel Prize was awarded, and included experiments performed to improve the general technique of intrathoracic operations.<sup>1</sup> Carrel emphasized the need for physiologic conditions, rigid asepsis, and precise tissue handling techniques while performing vascular surgery in the chest. He described the first experimental coronary bypass operation on the following words:

■ *In certain cases of angina pectoris, when the mouth of the coronary arteries is calcified, it would be useful to establish a complementary circulation for the lower part of the arteries. I attempted to perform an indirect anastomosis between the descending aorta and the left coronary artery. It was, for many reasons, a difficult operation. On account of the continuous motion of the heart, it was not easy to dissect and to suture the artery. In one case I implanted one end of a long carotid artery, preserved in cold storage, on the descending aorta. The other end was passed through the pericardium and anastomosed to the peripheral end of the coronary, near the pulmonary artery. Unfortunately, the operation was too slow. Three minutes after the interruption of the circulation, fibrillary contractions appeared, but the anastomosis took 5 minutes. By massage of the heart, the dog was kept alive. But he died less than 2 hours afterward. It shows that the anastomosis must be done in less than 3 minutes.*

He speculated that coronary artery bypass might be successfully performed by using a Payr's cannula or by placing the heart in a condition of anemia. He assigned operations on the coronary arteries to the most complex category of experimental cardiac operations because of heart motion. These important observations of Carrel were destined to lie dormant for more than 4 decades. The first operation performed for the relief of angina in humans was proposed by

S121







**TABLE 2. Important First Operations for Coronary Artery Disease in Man**

Date Performed	Date Reported	Surgeon	Operation
April 2, 1916	1920	Jonnesco <sup>3</sup>	Left cervical sympathectomy
March 24, 1933	1933	Berlin <sup>5</sup>	Thyroidectomy
February 13, 1935	1935	Beck <sup>7</sup>	Cardiac abrasion and muscle flap
April 19, 1939	1941	Fauteux <sup>18</sup>	Coronary vein ligation
1952	1952	Murray <sup>12</sup>	Internal mammary artery implant
1950	1955	Vineberg <sup>13</sup>	Internal mammary artery implant
1939	1955	Zoja and Cesa-Bianchi <sup>8</sup>	Internal mammary artery ligation
October 29, 1956	1957	Bailey <sup>24</sup>	Coronary endarterectomy
February 12, 1959	1960	Dobost <sup>26</sup>	Excision of syphilitic overgrowth of coronary ostia
1958	1961	Senning <sup>27</sup>	Vein patch enlargement of coronary arteries
1964	1967	Kolessov <sup>28</sup>	Internal mammary artery to coronary artery bypass
May 9, 1967	1969	Favaloro <sup>29</sup>	Saphenous vein aorta to coronary bypass
November 16, 1964	1973	Garrett <sup>31</sup>	Saphenous vein aorta to coronary bypass
April 4, 1962	1974	Sabiston <sup>32</sup>	Saphenous vein aorta to coronary bypass

*Robert H. Jones; Annals of Surgery, Vol. 238, N° 6S, December 2003*



Keynote Lecture Series

# The history of arterial revascularization: from Kolesov to Tector and beyond

Brian F. Buxton<sup>1,2,3</sup>, Sean D. Galvin<sup>1</sup>

<sup>1</sup>Department of Cardiac Surgery, The Austin Hospital, Heidelberg, Victoria, Australia; <sup>2</sup>Epworth Research Institute, Epworth Hospital, Melbourne, Victoria, Australia; <sup>3</sup>University of Melbourne, Melbourne, Victoria, Australia

*Corresponding to:* Professor Brian F. Buxton. Epworth Hospital, 59 Erin Street, Richmond, Victoria, Australia. Email: brianbuxton40@gmail.com.au.

Coronary artery bypass grafting (CABG) is the one of the most effective revascularization strategies for patients with obstructive coronary artery disease. Total arterial revascularization using one or both internal thoracic and radial arteries has been shown to improve early outcomes and reduce long-term cardiovascular morbidity. Although CABG has evolved from an experimental procedure in the early 1900's to become one of the most commonly performed surgical procedures, there is still significant variation in grafting strategies amongst surgeons. We review the history and development of CABG with a particular emphasis on the early pioneers and the evolution of arterial grafting.

**Buxton and Galvin *Ann Cardiothorac Surg* 2013;2(4):419-426**





### Key Pre-CABG Developments

**1880**  
**Langer**  
Collateral Circulation  
Around Coronary Plaque



**1910**  
**Carrell**  
Vascular  
Anastomosis



**1916**  
**Jonnesco**  
Surgical  
Sympathectomy



**1939**  
**Fieschi**  
IMA  
Ligation



**1946**  
**Vineberg**  
Direct Implantation  
of LIMA into LV



**1953**  
**Gibbon & Gibbon**  
First In-Human Application  
of Heart-Lung Machine



### The Birth of CABG

**1960**  
**Goetz**  
RIMA to RICA  
Tantalum Ring Anastomosis



**1962**  
**Sabiston**  
SVG to RCA  
Hand-Sewn



**1964**  
**Garrett/DeBaakey**  
SVG to LAD  
Hand-Sewn



**1964**  
**Kolesov**  
RIMA to RICA  
Hand-Sewn



**1968**  
**Green**  
LIMA to LAD  
Hand-Sewn



### The Growth of CABG

**1970s**  
**CABG vs. Medical  
Therapy Trials**  
1972-1974 VA Coop Trial  
1973-1976 European Coronary  
Surgery Study  
1975-1979 CASS Trial

**1970s**  
**Buckberg**  
Myocardial  
Protection



**1972**  
**Favaloro**  
~1700 CABGs



**1973**  
**Carpentier**  
Radial Artery  
Conduit



**1985**  
**Buffolo/Benetti**  
First Large Series  
of Off-Pump CABG



**1986**  
**Loop**  
Superiority of  
LIMA-to-LAD



### Continued Evolution of CABG

**1997**  
**Subramanian**  
MIDCAB



**1999**  
**Lytle**  
BIMA Utilization



**2009**  
**Serruys & Mohr**  
SYNTAX Trial



**2010**  
**Taggart**  
ART Trial



**2011**  
**Jones**  
STICH Trial



**2012**  
**Fuster**  
FREEDOM Trial



### Continued Evolution of CABG

**2013**  
**Diegeler/Lamy**  
GOPCABE/CORONARY  
Trials



**2015**  
**Park**  
BEST Trial



**2016**  
**Sabik & Kappetein**  
EXCEL Trial



**2016**  
**Holm**  
NOBLE Trial



**2019**  
**Zenati**  
REGROUP Trial



**20 Million  
CABG Operations  
Have Been  
Performed  
Worldwide**





*'I have always believed in team work. **'We' is more important than 'I'.** In medicine the advances are always the result of many efforts accumulated over the years'*

**René G. Favaloro**

**Circulation, 1998;98:466-478**





# 1962 – 1971 Cleveland Clinic




**William L. Proudfit, MD**



**F. Mason Sones Jr, MD**



**Donald B. Effler, MD**





# Effect of Coronary Artery Bypass Graft Surgery on Survival


Overview of 10-year Results from Randomised Trials

“This overview has shown that a policy of **routine early CABG** surgery **improves survival over a policy of initial medical therapy** (with delayed surgery for advanced symptoms). The benefits are especially pronounced in patients with more extensive coronary disease or ischaemia and in those who have clinical or angiographic features indicating high or moderate risk”.

**Salim Yusuf, MD., David Zucker, MD., Peter Peduzzi, MD., et al: The Lancet, 1994; 344: 563-570.**




# Medical treatment evolution



ACEIs: Angiotensin-converting enzyme inhibitors; ASA: acetylsalicylic acid ; ARNi: Angiotensin Receptor-Neprilysin Inhibitor  
CAD: coronary artery disease



# LIMA-LAD vs All SVG SURVIVAL



Loop et al, 1986




# SVG PATENCY

TRIAL	1 yr.	5 yr.	10 yr.
RAPS Trail (ACC 2011)	86%	82%	-
VA (JAMA 2011)	89%	-	-
RSVP (Circ 2008)	-	86%	-
RAPCO (JTCVS 2003)	-	84%	-
CASCADE (Circ 2010)	94%	-	-
CCF (Loop et al, 1986)	80%	76%	67%




# INCOMPLETE REVASCULARIZATION AND SURVIVAL

## THREE VESSEL DISEASE - CASS REGISTRY



# SURVIVAL AND REOPERATION 1 vs 2 IMA GRAFTS



Lytle et al. J Thorac Cardiovasc Surg 1999;117:855-872

www.fundacionfavaloro.org



# Six-year Survival Percentages $\pm 1.96$ by Number of Diseased Vessels, Number of Proximal Arterial Segments, and Left Ventricular Score

TABLE VI  
6-yr Survival Percents  $\pm 1.96$  SE by Number of Vessels Diseased, Number of Proximal Arterial Segments Diseased, and Left Ventricular Wall Motion Score  
(Number of Patients in Cell at Enrollment)

No. diseased vessels	No. proximal segments diseased	Left ventricular score			Total
		5-11	12-16	17-30	
0	0	93 $\pm$ 2 (1,836)	76 $\pm$ 13 (45)	78 $\pm$ 27 (9)	(1,890)
1	0	92 $\pm$ 2 (1,430)	81 $\pm$ 8 (219)	65 $\pm$ 20 (36)	(1,685)
1	1	90 $\pm$ 3 (796)	76 $\pm$ 9 (204)	55 $\pm$ 19 (65)	(1,065)
2	0	81 $\pm$ 6 (652)	49 $\pm$ 22 (128)	52 $\pm$ 18 (37)	(817)
2	1	86 $\pm$ 4 (617)	67 $\pm$ 10 (188)	54 $\pm$ 14 (71)	(876)
2	2	72 $\pm$ 9 (234)	51 $\pm$ 14 (102)	43 $\pm$ 20 (39)	(375)
3	0	76 $\pm$ 10 (238)	53 $\pm$ 12 (96)	25 $\pm$ 36 (29)	(363)
3	1	74 $\pm$ 7 (371)	43 $\pm$ 12 (191)	47 $\pm$ 13 (71)	(633)
3	2	66 $\pm$ 8 (297)	47 $\pm$ 9 (165)	24 $\pm$ 13 (74)	(536)
3	3	57 $\pm$ 13 (156)	29 $\pm$ 14 (93)	16 $\pm$ 14 (46)	(295)
					(8,335)



# Six-year Survival Percentages $\pm 1.96$ by Number of Diseased Vessels, Number of Proximal Diseased Arterial Segments, and Left Ventricular Score




TABLE VI  
*6-yr Survival Percents  $\pm 1.96$  SE by Number of Vessels Diseased, Number of Proximal Arterial Segments Diseased, and Left Ventricular Wall Motion Score (Number of Patients in Cell at Enrollment)*

No. diseased vessels	No. proximal segments diseased	Left ventricular score			Total
		5-11	12-16	17-30	
3	0	76 $\pm$ 10 (238)	53 $\pm$ 12 (96)	25 $\pm$ 36 (29)	(363)
3	1	74 $\pm$ 7 (371)	43 $\pm$ 12 (191)	47 $\pm$ 13 (71)	(633)
3	2	66 $\pm$ 8 (297)	47 $\pm$ 9 (165)	24 $\pm$ 13 (74)	(536)
3	3	57 $\pm$ 13 (156)	29 $\pm$ 14 (93)	16 $\pm$ 14 (46)	(295)
					(8,535)

Ringqvist et al; J Clin Invest; 71: 1854; 1983


# Medical treatment evolution



ACEIs: Angiotensin-converting enzyme inhibitors; ASA: acetylsalicylic acid ; ARNi: Angiotensin Receptor-Neprilysin Inhibitor  
CAD: coronary artery disease




## All-cause Mortality



Patients at risk:

MED	602	532	487	435	404	357	315	274	248	164	82	37
CABG	610	532	487	460	432	392	356	312	286	205	103	42

Figure S2: Kaplan-Meier Plot for All-Cause Mortality



Number at risk

PCI	347	317	287	198	143	87	37	14	3
OMT	353	315	291	204	155	93	36	11	2

OMT – optimal medical therapy, PCI – percutaneous coronary intervention



**OPCAB**

**TAR**

**MIDCAB**

**TECAB**


**Da Vinci Surgical System  
IMA Harvesting  
LIMA – LAD**

**Hybrid Revascularization: LIMA – LAD  
stent RCA Cx**






# CABG vs PTCA in 11.518 patients from 11 RCT



Head SJ et al., Lancet 2018; 391: 939-48


# PCI vs. CABG in Patients With Three-Vessel or LM CAD



Timeline of achievements that improve or may improve outcome in PCI and CABG during the years of follow-up for the SYNTAXES trial in parallel with the incidence of death at 1, 3, 5, 10, and 12.9 years post-randomisation based on published data. ART, Arterial Revascularization Trial; BIMA, bilateral internal

*CABG provided better (more complete) revascularization and better long-term survival compared with PCI.*


<https://www.acc.org/latest-in-cardiology/articles/2019/12/17/08/40/pci-vs-cabg-in-patients-with-three-vessel-or-lm-cad>








Fr









00.00.01, 36309, Special Procedures


SANTANA ROBERTO ESTEBAN  
251763 M 05-11-1946


Left Coronary 15 fps Me  
13-1

Fram









# Current Status of CABG



**Heart Team: cardiac surgeon &  
clinical & invasive cardiologist**

**CABG remains the standard of care  
for selected patients with complex CAD**

**LIMA-LAD standard practice**

**BIMA incremental**

**RA is better than SVG**


**ASA & Statins Improve SVG Patency**

**Complete revascularization important**





**Atherosclerosis is a  
progressive disease**







He's one of the busiest men in town. While his doot may say *Office Hours 2 to 7*, he's actually on call 24 hours a day.

The doctor is a scientist, a diplomat, and a friendly sympathetic human being all in one, no matter how long and hard his schedule.



*According to a recent Nationwide survey:*

# MORE DOCTORS SMOKE CAMELS THAN ANY OTHER CIGARETTE

DOCTORS in every branch of medicine—113,597 in all—were queried in this nationwide study of cigarette preference. Three leading research organizations made the survey. The gist of the query was—What cigarette do you smoke, Doctor?

*The brand named most was Camel!*

The rich, full flavor and cool mildness of Camel's superb blend of costlier tobaccos seem to have the same appeal to the smoking tastes of doctors as to millions of other smokers. If you are a Camel smoker, this preference among doctors will hardly surprise you. If you're not—well, try Camels now.



Your "T-Zone" Will Tell You...

T for Taste . . .  
T for Throat . . .

that's your proving ground for any cigarette. See if Camels don't suit your "T-Zone" to a "T."



**CAMELS** *Costlier Tobaccos*

boredpanda.com







\* The figures quoted have been checked and certified to by LYBRAND, ROSS BROS AND MONTGOMERY, Accountants and Auditors.

**20,679\*** Physicians  
*say* “**LUCKIES**  
are *less irritating*”


“**It's toasted**”

Your Throat Protection against irritation against cough



## Leading causes of death globally


○ 2000 ● 2019



Source: WHO Global Health Estimates.



## Leading causes of death in upper-middle-income countries




Source: WHO Global Health Estimates. Note: World Bank 2020 income classification.

<https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>



## Leading causes of death in high-income countries

○ 2000 ● 2019



Source: WHO Global Health Estimates. Note: World Bank 2020 income classification.

<https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>

[www.fundacionfavaloro.org](http://www.fundacionfavaloro.org)

# The World is Getting Fatter



250\*  
MILLION  
PEOPLE



1980

904\*  
MILLION  
PEOPLE

2008

\* number of people who are either overweight or obese

## OBESITY KILLS!

7 common diseases due to obesity:

- Arthritis
- Cancer
- Infertility
- Heart Diseases
- Back Pain
- Diabetes
- Stroke

# Junk Food








**“What we created,  
I believe, is a culture of  
“healthy eating ” to fight a  
“toxic environment” of junk  
food and too little exercise”**

*Dr. Valentín Fuster*





# *Evaluation of the Program SI! for Preschool Education: A School-Based Randomized Controlled Trial (Preschool\_PSI!)*



*The SI Program for Preschool Education was an intervention that was both school and home based designed to improve the habits, knowledge and attitudes in four key areas: **Food (diet), Physical Activity, Knowledge of the Body and Managing Emotions.***

*The intervention was implemented in children from three 3-5 years of age, with their parents and teachers.*

*To evaluate the efficacy of this intervention, the principal aim of the phase of evaluations was to quantify the behavior changes in the three groups/populations mentioned.*

*The evaluation had been designed according to the controlled intervention model, in which twenty-four schools from the Community of Madrid were randomized to implement the Program si! for Preschool Education or to function as control schools.*



STUDY PROTOCOL

Open Access

# A cluster randomized trial to evaluate the efficacy of a school-based behavioral intervention for health promotion among children aged 3 to 5

José L Peñalvo<sup>1\*</sup>, Gloria Santos-Beneit<sup>1,2</sup>, Mercedes Sotos-Prieto<sup>1,2</sup>, Ramona Martínez<sup>2</sup>, Carla Rodríguez<sup>2</sup>, Manuel Franco<sup>1,3,4</sup>, Pedro López-Romero<sup>1</sup>, Stuart Pocock<sup>1,5</sup>, Juliana Redondo<sup>1</sup> and Valentín Fuster<sup>1,6</sup>

**Table 1 Summary of the Program SII Intervention components**

Strata	Objectives	Intervention activities	Intervention materials	Minimum hours
Children	Acquiring KAH regarding the 4 components of Program SII	- Classroom instruction	- Didactic units. Including 7 key activities per unit, and associated resources: Sesame Street audiovisuals, books and games, and cooking workshops, and tales on healthy living	70
		- Health Fair	- Sesame Street Emotion cards	
Parents	Improving KAH regarding the 4 components of Program SII	- Program SII by Dr. Fuster (video)	- Informative letters and leaflets	12
		- Health Fair	- Program SII website - Healthy tips	
Teachers	Improving KAH regarding to the 4 components of the PSII	- Program SII by Dr. Fuster (video)	- Training booklet, and associated audiovisual material	30
		- Program SII capacity building: intensive training for teachers, and SHE Foundation's liaisons	- Intranet continuing education tools	
		- Continuing counseling from SHE Foundation's staff to the liaisons	- Program SII website	
		- Health Fair		
School	Improving the school environment in regards of healthy environment	- Program SII by Dr. Fuster (video)	- Document of healthy recommendations in schools	20
		- Periodical meetings between principals and SHE Foundation's liaison	- Program SII website	
		- Health Fair		

KAH, Knowledge, attitudes and habits.



RESEARCH ARTICLE

Open Access

## The Program SI! intervention for enhancing a healthy lifestyle in preschoolers: first results from a cluster randomized trial

José L. Peñalvo<sup>1\*</sup>, Mercedes Sotos-Prieto<sup>1,2</sup>, Gloria Santos-Benét<sup>1,2</sup>, Stuart Pocock<sup>3</sup>, Juliana Redondo<sup>1</sup> and Valentín Fuster<sup>1,4</sup>

### Abstract

**Background:** Unhealthy lifestyles contribute to the development of cardiovascular risk factors, whose incidence is increasing among children and adolescents. The Program SI! is a long-term, multi-target behavioral intervention to promote healthy lifestyle habits in children through the school environment. The objective of the study is to evaluate the efficacy of this intervention in its first phase, preschoolers.

**Methods:** Cluster-randomized controlled trial in public schools in the city of Madrid, Spain. A total 24 schools, including 2062 children (3–5 years), 1949 families, and 125 teachers participated in the study. Schools were assigned to their usual school curriculum or to engage in an additional multi-component intervention (Program SI!). The primary outcome of this trial is 1-school year changes from baseline in scores for children's knowledge, attitudes and habits (KAH). Secondary outcomes are 1-school year changes from baseline in scores for knowledge, attitudes, and habits among parents, teachers, and the school environment.

**Results:** After 1-school year, our results indicate that the Program SI! intervention increases children's KAH scores, both overall (3.45, 95% CI, 1.84-5.05) and component-specific (Diet: 0.93, 95% CI, 0.12-1.75; Physical activity: 1.93, 95% CI, 1.17-2.69; Human body: 0.65, 95% CI, 0.07-1.24) score.

**Conclusions:** The Program SI! is demonstrated as an effective and feasible strategy for increasing knowledge and improving lifestyle attitudes and habits among very young children.

**Trial registration:** NCT01579708, Evaluation of the Program SI! for Preschool Education: A School-Based Randomized Controlled Trial (Preschool-SI!).

**Keywords:** Health education, Health promotion, Children's health



## THE PRESENT AND FUTURE

### JACC STATE-OF-THE-ART REVIEW

# Lessons Learned From 10 Years of Preschool Intervention for Health Promotion



## JACC State-of-the-Art Review

Gloria Santos-Beneit, PhD,<sup>a,b,c</sup> Rodrigo Fernández-Jiménez, MD, PhD,<sup>c,d,e</sup> Amaya de Cos-Gandoy, MSc,<sup>a,c</sup> Carla Rodríguez, MSc,<sup>a</sup> Vanesa Carral, PhD,<sup>a</sup> Patricia Bodega, MSc,<sup>a,c</sup> Mercedes de Miguel, MSc,<sup>a,c</sup> Xavier Orrit, PhD,<sup>a</sup> Domenec Haro, BA,<sup>a</sup> José L. Peñalvo, PhD,<sup>f</sup> Juan Miguel Fernández-Alvira, PhD,<sup>c</sup> Carles Peyra, BA, MBA,<sup>a,b</sup> Jaime A. Céspedes, MD,<sup>g,h</sup> Alexandra Turco, BS,<sup>b</sup> Marilyn Hunn, BS,<sup>b</sup> Risa Jaslow, MS, RDN,<sup>b</sup> Jorge Baxter, PhD,<sup>i</sup> Isabel Carvajal, MSc,<sup>a</sup> Valentin Fuster, MD, PhD,<sup>a,b,c</sup>

### ABSTRACT

Implementing a health promotion program for children is a complex endeavor. In this review, we outline the key lessons learned over 10 years of experience in implementing the SI! Program (Salud Integral-Comprehensive Health) for cardiovascular health promotion in preschool settings in 3 countries: Colombia (Bogotá), Spain (Madrid), and the United States (Harlem, New York). By matching rigorous efficacy studies with implementation science, we can help bridge the divide between science and educational practice. Achieving sustained lifestyle changes in preschool children through health promotion programs is likely to require the integration of several factors: 1) multidisciplinary teams; 2) multidimensional educational programs; 3) multilevel interventions; 4) local program coordination and community engagement; and 5) scientific evaluation through randomized controlled trials. Implementation of effective health promotion interventions early in life may induce long-lasting healthy behaviors that could help to curb the cardiovascular disease epidemic. (J Am Coll Cardiol 2022;79:283-298) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



# And what for the future?







**FUNDACIÓN  
FAVALORO**



**UNIVERSIDAD  
FAVALORO**

**Thank you for your attention.**